Healthcare & Life Sciences~3 peopleSan Francisco, CA, USA
We build better immunotherapies
Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases. Our cis-targeting platform aims to enable selective activation of specific immune cell types, addressing the inherent limitations of otherwise pleiotropic immunotherapies that act on multiple cell types. Our approach has the potential to precisely direct different immune mediators against a range of target immune cell-types and create best-in-class immunotherapies in cancer, autoimmune and infectious diseases.
Asher Bio is backed by Third Rock Ventures and is located in South San Francisco.
Pressurl: https://news.google.com/rss/articles/CBMingFBVV95cUxPSnRrek80NHV6cFRxa3dGTmo2WTlGa1VWS1FTNEdxR0tTZU5WVkdoTTdXbDllMGZfWnVwaGJQdDZvejdfN2J2VWt4X1VhalNlTzVLY0FlWm15YmJ4QllPaHFqbFhoYWRiMENWejJNZWthel9zQjBubXVpSDFOSzl5U3JNTVpXbG80MzdoSlBnVjE5VS1yVFR1V2xubHdkUQ?oc=5 · headline: Lonza collaborates with Asher Biotherapeutics Inc · publication: European Biotechnology Magazinegoogle_news · 10/15/2026
Pressurl: https://news.google.com/rss/articles/CBMiwwFBVV95cUxObU5vNnRacThyYnZSNTFGSW5uWDlGNktIU1NGaTRCWDV0ZzNFdjAwMDZXVjZrdVZtTVR4dmNfdEd5ZkQxZG9rejZaaUdpWkoyWHJYNGpBa2NvYjBBSzVzTWh5RjlGZFNMY01nUi1vaVJmSGVMeTd0Yk9SdEtxMXhYZ0t3elI1akRfNzFxYnZmVFZwSi1GWXFTRERqUF9BczltdEJtVzlxTGp3OWNiS2tzRk9pQWgzT3hTQy1WSG1LTngxbUk?oc=5 · headline: Asher Bio snags $108M series B for immunotherapy programs, push into the clinic · publication: Fierce Biotechgoogle_news · 10/15/2026
Pressurl: https://news.google.com/rss/articles/CBMizgJBVV95cUxNdkJzT21fTVpLbG1RZFlBcmFqWEF0eWlBcWVuaWtmNUdlRW5VNzVYejJvSVdDYk83VlZVWl9MQkRuQ1FFd1pnR3lTTmRQMTNtN3hKaF9tYnFfTWZrOXVLd01oTDJ3VmJWLTF0d3JIMFZDQm4yaEgySUhlMmpoNUIwTzlwQzJmNGQzWTZQOFpnZjFXMDNxd0JoaVU5MmFaY1JHeFBnSzJ2R0Z5cHQyaGstNmJnemFsTEc3ekEtckZBQjhRZ1FnMjIwUmVrVE1RT2RVVUdlaDI2TDhiVnNuWWxUdmJYN1h4VEczVm5MWFNsNzdYWjlJQmlSU294enZJYjhXMkNjaVdhNVZXSy1ta0xUOTlhQW5kcG16MnYxb29ibXRIR2FMY1VSWUsxckF2UFJFUlNNWGVDampXejdRZFJfejQ2RURKcUZHY2ZVb1Zn?oc=5 · headline: Asher Bio Announces Clinical Supply Agreement to Enable Evaluation of Etakafusp Alfa (AB248) in Combination with Rilvegostomig in a Global Phase 1b/2 Study in Non-Small Cell Lung Cancer (NSCLC) · publication: BioSpacegoogle_news · 10/15/2026
Pressurl: https://news.google.com/rss/articles/CBMivgFBVV95cUxNT0xHdDNSZmZCRTRmejBVM3R5cUpNaHhWV0Nmb0dnNTgtc1pweW5UUzNTX09RVnA2Vjc4VjM2MzhCRGdHWVJmbDNOM0RzVjZZaGo2NGo4bmU2aUl5X3ZhOU00NDZTZGpNM1VyVzE4clFCZkdBY0ZlUU1lSlpwRHU5dnVMRnItSHhQdmZxRTVvUHk5cFZ0Y2xkclcwa2FmQV9pVTBUamJMT0VpYTNfdkprSUJ2WFRlcUI5UkpibGdn?oc=5 · headline: Asher Bio Appoints Andrea Pirzkall, M.D., as Chief Medical Officer · publication: Business Wire
google_news · 10/1/2026
Pressurl: https://news.google.com/rss/articles/CBMiqAFBVV95cUxQUDJ3UEpSSmNleEp6RGVoSUdMci12ZjBkZ0piX3JoU25fclFXcXpMMXJnc0JVd1FFZU54OUM1alNUNUZJYkFZR3d6Wkc0OVk4ejNtNEJESTlobk9Ma3hEazlvc2c5N3gwdFhDYzEyWTFWTnhXM2FMYUFaVHpzRXVlMGhGVUNvdWNfRTBjTlVRV3hNQ0hjd0NrM1JselhiaHZIQy0wQ0o4eDI?oc=5 · headline: YC Demo Day 2: All 25 Bay Area pitches, from a hot virtual office startup to a cool stroke treatment · publication: The Business Journalsgoogle_news · 9/15/2026
Pressurl: https://news.google.com/rss/articles/CBMisgFBVV95cUxObTF4NFNYN01qdlJJNFJlTU5SXzdGNm85Qm53djl3amRhY29BeDU0VUxZaXlvS0JWX2lsZjNfVk1FcUpiR3FuNTl0LTlzV3hQa0NZU2kyT1F3eFZnNkt3WnhpNkF5UzF2elFjazlDSDhnX01oUHpEc3JwM1p2MmZNTm1NSU5PZ2FpczNFaHpjbjVlSkg5ZGJyUTNaVkVYeWlSbDVUWUFSWEpHQTA2akpqTlp3?oc=5 · headline: New twist on old cancer target brings $55M to 'happy, blessed' startup by Pfizer vets - San Francisco Business Times · publication: The Business Journalsgoogle_news · 9/15/2026
Pressurl: https://news.google.com/rss/articles/CBMipwFBVV95cUxPRzNVeG1XZUxLQ0RHcm9qY1F5bzVJUVdLVmQxVEdTMThWMm1GNkVBNnJaeDBoVmhFeDNxWmFBZWZkR05UVVkzMXRNYkducHJPb25LM3VTOUlZR1JLTFgzM1ctSDhLN1pGQzAxM01kZjJfbGFtaTJSeVBDZXl1RGlTTDBhZVY4Z0J1Vy0wNkx4QmJzY25KMmxXYmpwSTRSLWpPWnpOdHJUbw?oc=5 · headline: Asher Bio Appoints Andrea Pirzkall, M.D., as Chief Medical Officer · publication: citybizgoogle_news · 9/15/2026
Pressurl: https://news.google.com/rss/articles/CBMigwJBVV95cUxQSTZQcjZ0WUxKVlBMdDVma2NOZ0dzM1d2TVRGTm9WaDZlUTRHaG5qSzFhejRCY3FWdENuMXB3aEhKcTJQZVBxQVItZ2c3OWFJLVZnLWhtZkdEbnRpbUlCUmRfUlRXNmptc0FTYzN5VDJHRHFiZHVFR1NVOVZWQllmRXU1bjBncHFHbEpyMFhyZ3V5dXhGN1ZJSENiYUJwdWQweUJGQS1BWGw1T2NhclFaQnBFWGtDTXBiR1lLYURrZm9MSDBzZGktLWE3QXZQYlREVW5EN3V1T1h3Vm1weW9LOUZrOU0yNVBNSHN3akZUcC03c0h0TGc4d3VObV92cVdRcVBv?oc=5 · headline: Asher Bio Presents Promising New Preclinical Data for Cis-targeted Cancer Immunotherapy AB821 at SITC Annual Meeting · publication: Business Wiregoogle_news · 9/15/2026
Pressurl: https://news.google.com/rss/articles/CBMiZ0FVX3lxTE5tR3dnT3l5X2JLZUxud0xLaUJyREgtRlRYS3Zvd3RDbXlXSUdadDFRNTFkNzdCZktvN195cWJnUmVIdHN2X2VaeWZoVWRTNGFSQ2xOMXFCdUNPbVNUUVp3Q3ctTjBqY1k?oc=5 · headline: CD8 cis-targeted IL-2 drives potent antiviral activity against hepatitis B virus · publication: science.orggoogle_news · 9/15/2026
Pressurl: https://news.google.com/rss/articles/CBMivgFBVV95cUxPMDk5dHdWNDkyMG1nYnlvc3RZOVlPckpDN292SnpuQ0lvcmhuMHRVNjA5SklQNkNVYkhvdVg5NndPLWJPc3JlNDJ0SzdEcVBQcFhVTlpLWDMwQXNOblR3dy1Ea3Y4di1yRHNkNG9ldmZ6eUFkSFFpTlZSdFQ2VVdzSTRFSmNqNC1hWmp3d0Uza1dfWlFLOUVRMExseFY2cVFud28xVmhuS0V2YVhXbUJBTzlWbDBScGJiemM5OUt3?oc=5 · headline: Asher Biotherapeutics AB248 & Rilvegostomig in NSCLC: Phase 1b/2 Study Announced · publication: The Clinical Trial Vanguardgoogle_news · 9/15/2026
Pressurl: https://news.google.com/rss/articles/CBMipAFBVV95cUxPbjc3WTc3N1g0VVA0aHRCSkxic3JVakF1NFZvbVFnNWo2SmxDTTlxMjVZRmZWZmVQSGg4TE9KSHFrNGg4UzVtTU14ME1nbUwzMmFfblVibm9BV0Q3R3RwY3o2aFVKU1FOZXZGZmZsZEVoV0F2amRDUTFSS2ZzanR6MDRXeUdOX1kyeEItaC1XVUQwa2otV2gyekVsel9EVXZaY0ctdA?oc=5 · headline: Asher drops 60% of staff to zero in on lead immunotherapy · publication: Fierce Biotechgoogle_news · 9/15/2026
Pressurl: https://news.google.com/rss/articles/CBMilAFBVV95cUxQVlJzci1aV29oX3R3ZE04UFc0SXk4UXhaYndMWUU4d212X0lkS3FzNVVpcGVUU1o3MmZqeFotZW05eUZLNkNuZm5zZDZxblRXcllWczlqTVpxamh2NVN0WDNtcnppT0h6cklCX3NwRUNKX2Rwd1ZIRVNRU2hYbFRuQU8xMjFnTEhmN1pZUHVwbjlnYzJj?oc=5 · headline: Asher Bio Appoints Bob Deresiewicz, M.D., To Its Board · publication: citybizgoogle_news · 9/15/2026